The Influence of Zoledoronate and Teripartide on Gd T Cells in Mice

      The cause of bisphosphonate-related osteonecrosis of the jaw (BRONJ) is poorly understood. However, since nitrogen-containing bisphosphonates (NBPs) have been shown to reduce bone remodeling and angiogenesis, the suppression of bone turnover and jaw angiogenesis by NBPs has been proposed as an underlying mechanism for BRONJ. Although innate immunity has a critical role in the inflammation process, few studies have investigated the possibility that BRONJ might reflect an immune response. However, in 2012 it was reported that gd T cells, which are a subset of T cells, showed a significant and permanent decline, both in proportion and in absolute number, following infusion of an NBP. Regarding the treatment of BRONJ, although teriparatide, which is a recombinant form of parathyroid hormone that promotes bone growth, has not been widely used in the treatment of BRONJ, there have been a few reports of teriparatide use for the treatment of BRONJ. Administration of teriparatide for the resolution of BRONJ was first described by Harper and Fung in 2007. Subsequently, the administration of teriparatide has been documented in independent case reports. In this study, we analyzed lymphocytes including gd T cells, which are of the same origin as osteoclasts, like all typical immune cells, and we focused on the relationship between innate immunity and NBP and teriparatide treatments, and their effects on inflammatory cytokine production.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Oral and Maxillofacial Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect